Aurora Cannabis Investor Presentation, January 2018

1. JA N UARY 2018
AGILITY
INNOVATION
EXECUTION
AND EXPANSION
Building a globally dominant
cannabis company

2. Forward Looking Statements
This Presentation (the “Document”) by Aurora Cannabis Inc. (“Aurora” or the “Company”) has been compiled by management of the Company solely for information purposes. The Document has been prepared and dated as of March 31, 2017, and the
information contained herein is current as of such date only. The Document under no circumstances is to be construed to be an offering of securities. Neither this Document, nor its delivery to the recipient shall constitute an offer to sell, or the solicitation of an
offer to buy the assets described herein. It is provided solely for use by prospective investors in considering their interest.
The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its business and does not purport to contain all the information that prospective investors may require. Prospective investors
should conduct their own investigation and analysis of the Company and its business and the information contained in this Document as well as any additional information provided by the Company.
This Document includes forward-looking statements within the meaning of certain securities laws, including the “safe harbour” provisions of the Securities Act (Ontario, Alberta and British Colombia) and other provincial securities law in Canada. These forward-
looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and
intentions. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import,
are intended to identify forward- looking statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain
material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. The Company strongly cautions readers not to place undue reliance on these
statements, as a number of important factors, many of which are beyond our control, could cause the Company’s actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such
forward-looking statements. These factors include, but are not limited to: general economic conditions; pending and proposed legislative or regulatory developments in Canada including the impact of changes in laws, regulations and the enforcement
thereof; reliance on funding models in Canada; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in
the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total patients and customers; technological change and obsolescence; loss of services of key senior management personnel;
privacy laws; structural subordination of common shares; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and
future sales of the Company’s securities.
The foregoing list of important factors that may affect future results is not exhaustive. When reviewing the Company’s forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential
events. Except as required by Canadian securities law, the Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by the Company or on the Company’s behalf. Such
statements speak only as of the date made.
The forward-looking statements contained in this Document should not be relied upon as representing the view of the Company or its management as of any date subsequent to the date of this Document. Neither the Company nor its management is under
any obligation, and neither undertakes, to update any of this information at any particular time. Neither the Company nor its management assumes any obligation to update or revise forward-looking statements should circumstances or estimates or
opinions changes.
None of the Company or its affiliated or related partnerships and corporations or their respective directors, officers, partners, employees, agents or representatives makes any representation or warranty as to the accuracy or completeness of the Document
or any statements, estimates or projections, and none will assume any liability for any representations (express or implied) contained in, or for any omissions from, the Document, or for any other written or oral communications transmitted to prospective
investors in the course of their evaluation of the Company and its business. An investor will only be entitled to rely on those representations and warranties contained in the definitive agreement or agreements which constitute the financing.
This presentation can not be copied, reproduced or distributed in whole or in part to others, at any time, without the prior express written consent of the Company.
To the extent that they are included in this document, certain financial metrics can be reported as non-IFRS measures, such as EBITDA (earnings before interest, taxes, depreciation and amortization). For the purposes of this Document, EBITDA is calculated as
revenue less cost of sales and operating expenses. The Company believes that these non-IFRS measures are appropriate measures of the operating performance of the Company. The Company’s calculation of these measures may differ from the
methodology used by other issuers and, accordingly, may not be comparable to such other issuers. The Company believes that these measures are appropriate measures of the Company’s operating performance because they facilitate an understanding of
operating performance without giving effect to certain non-cash and overhead expenses. None of these measures are equivalent to net income or cash flow from operating activities determined in accordance with IFRS.
Aurora Cannabis Inc. Management Presentation 2

3. EXCEPTIONALLY
WELL POSITIONED TO
CAPITALIZE ON THE
GLOBAL CANNABIS
OPPORTUNITY
1VIII Capital, Cannabis Sector, July 2017
CANADA
$12 B1
EU
$37 B1
ROW
$110 B1
PROJECTED MARKET POTENTIAL

4. 4
AGILITY INNOVATION EXECUTION EXPANSION
Talented, experienced management team driving the sector's
fastest growth in customers, revenues and shareholder value

5. Agility
• Fastest ramp up, execution
and sales growth achieved
relative to other LP’s
• Focused strategy aimed at
capitalizing on vertical and
horizontal integration
opportunities internationally
and domestically
Aurora Cannabis Inc. Management Presentation 5
0 310
3,000
7,700
12,000
13,100
16,000
20,000
0
5,000
10,000
15,000
20,000
25,000
Jan '16 Feb '16 May '16 Aug '16 Dec '16 Mar '17 Jun '17 Sep '17
Aurora Active Registered Patients
Source: SEDAR filings
Fastest Growing LP’s – Sales License to 650kg/quarter

6. Aurora Cannabis Inc. Management Presentation 6
AURORA SKY
• World’s largest and most technologically
advanced cannabis cultivation facility
• Optimized for highest yield and lowest
cost per gram produced
AURORA VIE
• Specialty strains
• Yield-optimized indoor facility
AURORA MOUNTAIN
• First fully purpose-built indoor cannabis
facility
CUSTOMER SERVICE
• The Aurora Standard:
leading edge customer care
• Only LP with mobile app for
purchasing medical
cannabis
• Same-day delivery in
Calgary, Edmonton and
surrounding areas
• e-Commerce
• Product differentiation
RADIENT TECHNOLOGIES
(Strategic Partnership, 17.23% interest)
• Joint development of superior,
proprietary oil extraction process
• Faster, more efficient and higher
throughput
• Better terpene preservation
NamasteMD – exclusive white label use
for CanvasRx
Micron Waste Technologies (9%
interest) – low-cost environmentally
friendly treatment of organic waste
Establishing a world-leading brand, scale and efficiencies
Innovation Across all Operational Areas
CUSTOMER
EXPERIENCE
CULTIVATION Strategic
Partnerships

7. 7
STRONG REVENUE GROWTH
CAPITALIZATION
DOMESTIC EXPANSION
CAPITAL MARKETS PROGRESSION
GLOBAL EXPANSION
HORIZONTAL INTEGRATION
Scale, Reach & Differentiation
• Year on Year revenue growth 169% (Q1 2018/2017)
• > $700 M pro-forma cash and marketable securities balance to fuel
domestic and international expansion
• Construction of industry-leading facilities on schedule
• Pedanios acquisition - largest German distributor
• BC Northern Lights and Urban Cultivator acquisitions – proprietary
systems for indoor cultivation of cannabis and organic microgreens
• H2 Biopharma acquisition – expansion in Quebec
• Cann Group investment - first Australian licensed cannabis company
• Radient investment – superior extraction technology
• Hempco investment – ancillary product offerings and potential
access to substantial supply of low-cost CBD
• Namaste strategic supply, distribution and exclusive agreement to
white label NamasteMD platform
• Acquisition Larssen, formation ALPS, industry leading design and
consulting operation
• Denmark – 51% in JV building Europe’s largest cannabis facility
• Investment in TGOD – access to >20,000 kgpa premium organic
cannabis and potential to benefit from financial performance TGOD
• CannaRoyalty – access to drug delivery technologies
EXECUTION

8. Domestic Expansion
8
MOUNTAIN SKY VIE LACHUTE
Footprint
(square
footage)
55,000 800,000 40,000 48,000
Status Operational
since 2015
Completion by mid-
2018
First bays ready for
planting Dec 2017
Completed and
Licensed Nov 2017
First harvest
Jan/Feb 2017
Completion Q1
calendar 2018
Capacity 4,800 kg/yr 100,000+ kg/yr 4,000+ kg/yr 4,500+ kg/yr
Key features First purpose
built cannabis
facility
EU GMP
certified
Highly automated,
technologically
advanced cannabis
facility for optimized
yield and low cost
production built to EU
GMP standards.
Located at Edmonton
international airport
for superior domestic
and global distribution
logistics
Technologically
advanced,
specialty strains for
premium products
and medical
research
Completed to EU
GMP standards
Nearly
completed, state-
of-the art facility
to be completed
to EU GMP
standards
$ 3.0 Billion
medical cannabis market opportunity in
Canada1
$ 9.0+ Billion
adult consumer market opportunity in
Canada1
3.4 million Canadian marijuana users***
Nationwide legalization
Potential for new product forms & devices
Positioned for rapid growth of medical and adult consumer markets
Aurora Mountain one of only a few EU GMP Certified cannabis
production facilities
1 VIII Capital, Cannabis Sector, July 2017

9. Ancaster facility
Valleyfield facility
Strategic Partnership with TGOD – Further Capacity and
Differentiation Through Premium Organic Products
• Aurora is completing a strategic
investment in The Green Organic
Dutchman (TGOD)
• Aurora will own 17.62% of TGOD, with
option to increase interest to >50%
• Agreement includes supply agreement,
providing access to 20% of TGOD output
from Ancaster and Valleyfield facilities
• TGOD is building 820,000 sqft ALPS-
designed facility in Valleyfield, Quebec
• TGOD is completing expansion of
existing Ancaster (On) facility to 150,000
sqft
• Will have >100,000 kg per annum
production capacity
Aurora Cannabis Inc. Management Presentation 9
Larssen LtdG R E E N H O U S E E N G I N E E R I N G
MOTHER PLANT
PROPAGATION
VEGETATIVE
FLOWERING
BUILDING 1
SUPPORT
AREA
WASTE
MANAGEMENT
ENERGY
ROOM
HST
RAINWATER
RESERVOIR
BUILDING 2
Adding > 20,000 kg p.a.
in premium organic
cannabis product to
Aurora portfolio

10. INTERNATIONAL EXPANSION AND
PRODUCT DIFFERENTIATION
10

11. 11
Pedanios – Aurora’s Gateway
to the EU Cannabis Market
82 million
population Germany
>400 million
population EU
• Largest medical cannabis distributor in EU
• EU GMP certified for import, release and
distribution of cannabis
• Currently servicing >2,000 pharmacies in
Germany (exclusive suppliers of patients)
• Access to single largest federally legalized
medical cannabis market with population
> 82 million
• Broad insurance coverage for prescribed
medical cannabis
• Limited number of EU GMP certified
international producers currently serving
the German market
• Cornerstone acquisition for European
expansion strategy
• In phase 2 of tender process for German
cultivation license

12. 12
Aurora Nordic – Europe’s Largest Facility
at 1,000,000 Square Feet
82 million
population Germany
Nordic focus wth
option to export
to wider EU with
> 400 M people
• Aurora Nordic: 51/49 JV with Alfred
Pedersen, one of Europe’s largest
greenhouse growers of vegetables
(>100,000 kg per day)
• Licensed to produce as of Jan 1, 2018
• To construct ALPS-designed high-
technology facility
• At 1,000,000 sqft, this will be largest
cannabis facility in Europe
• Focused on Nordic countries and
export to rest of EU through Pedanios
• Built to EU GMP standards for export
• Prior to facility being completed, JV has
access to temporary greenhouse space
for cultivation of cannabis
JV Partner Recognized
as one of Denmark’s
leading entrepreneurs

13. CANN GROUP: Australian Market Opportunity
13
• 22.9% stake in Cann Group Ltd for
$6.6 million (initial investment at AUS
$0.30/share)
• Significant appreciation of initial
investment since listing
• Technical Services Agreement in place
• Possession of one of the first two Licenses
issued in Australia
• Cultivation, Sales, and R&D licenses
• 3 facilities contemplated
• First harvest completed
• Australia is a new market with significant
development potential
>24 million
population
AUSTRALIA
Aurora Cannabis Inc. Management Presentation
Date
Shares bought
(million)
Price Costs
Current
Price (Jan
9, 2017)
Current value
25-Apr-17 21.6 0.31 6.696 3.6 77.76
08-Dec-17 7.2 2.42 17.424 3.6 25.92
TOTAL/Averag
e
28.8 0.8375 24.12 3.6 103.68
330% return on investment

14. Vertical Integration – Aurora Larssen Projects Ltd. (ALPS)
• Formed following acquisition of Larssen Ltd.
• Global leading greenhouse engineering and
design consultancy
• Responsible for Aurora Sky
• Currently engaged by 15 cannabis
companies globally, including 5 LPs
• 30 year track-record delivering
technologically advanced, yield-optimized
greenhouse facilities for cannabis and other
horticultural sectors
• Tracking for $6M in Fiscal 2018 revenues
Aurora Cannabis Inc. Management Presentation 14
Creating a Global Turnkey Cannabis Cultivation Powerhouse

15. Horizontal Integration - Strategic Relationships
Hempco Food and Fiber Investment
• Potential future ownership > 50%
• Well-established, pioneer distributors of
hemp products
• Provides access to hemp – a large, low-cost
and sustainable source of CBD to support
growing demand for cannabis products
• Ancillary product offerings for horizontal
integration - nutritional supplements and
health-lifestyle products
Namaste
• Leading e-Commerce supplier of cannabis
vaporizers
• Serves growing need for smokeless solutions
and growing demand for ancillary products
• Promotes wider brand recognition in
anticipation of legalization of the adult
recreational market
• Now also acting as third-party distributor for
BCNL products
• Exclusive white label use of NamasteMd by
CanvasRx
Aurora Cannabis Inc. Management Presentation 15

16. FINANCIAL SECTION
16

17. Operating Metrics and Assumptions
AURORA MOUNTAIN:
• Consistent production at capacity during the last
two quarters
• Continued production expected at 4,800 kg/yr
AURORA SKY:
• First bays ready for planting
• First harvest and inventory build expected by April 2018
• Capacity of 100,000 + kg/yr expected by June 2019
VIE:
• Planting commenced November 2017
• First harvest and sales expected early 2018
• Capacity of approx 4,000 kg/yr expected by early 2019
LACHUTE FACILITY
• Further exposure to underserved Quebec market
with additional 4,500 kg/yr capacity and significant
expansion potential
• Facility to be completed to EU GMP standards
• First harvest expected Q2 calendar 2018
SALES PRICES:
• Sales prices in Canadian and Germany medical
markets expected to remain steady for several years
• Selling prices in Canadian adult consumer market
may vary by province depending on distribution
model
CASH PRODUCTION COST PER GRAM:
• As Aurora Sky ramps up, ACB’s average cash
production cost per gram expected to fall to below
$1.00/g

18. 18
Unit Economics
Current Aurora Metrics
Sales Price per Gram/Gram equivalent
Canada – CAD $9/g
Europe - > € 8/g (~CAD11.80/g)
Cash cost to produce (Q1 2018)
$1.73/g
Cash cost to sell (Q1 2018)
$1.92/g
Outlook
Sales price per gram/gram equivalent for dried
cannabis products expected to be stable with
global demand exceeding supply.
Higher margin expected on concentrates and
other derivative cannabis products.
Cost per gram expected to decrease with
automation, scale and yield expertise realized.
Long term SG&A costs not expected to escalate at
the same rapid pace of projected revenue and
market growth given regulatory marketing
restrictions and economies of scale.

19. Aurora Cannabis Inc. Management Presentation 19
$0.2
$1.2
$3.1
$3.9
$5.2
$5.9
$8.2
$0.0
$1.0
$2.0
$3.0
$4.0
$5.0
$6.0
$7.0
$8.0
$9.0
Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018
Sequential
Growth (%)
169%
YoY growth
for Q1 2018
457.1% 151.7% 26.5% 33.2% 14.7% 39.0%
Strong Revenue Growth
Revenue ($M)

20. Aurora Cannabis Inc. Management Presentation 20
Q1 2018 Q4 2017 Q3 2017 Q2 2017
# # # #
Active registered patients (1) 19,280 16,400 13,110 12,200
Grams sold 889,965 755,059 653,008 538,045
Grams produced (2) 1,009,585 1,164,683 846,849 670,322
(In CDN $000’s unless otherwise noted) $ $ $ $
Average net selling price per gram 8.22 7.45 6.64 5.96
Cash cost of sales per gram 1.92 2.09 2.31 2.56
Cash cost to produce per gram 1.73 1.91 1.91 2.13
Cash and cash equivalents 127,915 159,796 111,116 55,846
Working capital 169,674 170,142 126,530 60,060
Continuously Improving Metrics

21. Aurora Cannabis Inc. Management Presentation 21
Company invested in
Shares
bought
Average
price
Current
Value
RoI
# $ $ %
Radient Technologies 28.8 0.84 103.7 330
Cann Group 23.2 0.57 50.8 285
Hempco Food and Fiber 10.6 0.31 19.8 519
TOTAL $174.3 330%
Value Creation Through Strategic Investments
Exceptional investment track record
Currently completing investment agreements with TGOD and Micron Waste Technologies

22. OUR ASSETS
22

23. Aurora Mountain – First Large-Scale Purpose-Built EU GMP Certified
Cannabis Facility
sq. ft. purpose-built, state of the art facility
State of the art, scalable, EU GMP certified production facility
55,200
4,800kg
13
Current annual capacity
Licensed grow rooms: 10 flower, 1 clone,
1 mother, 1 micro-propagation
sq. ft. of land available for facility expansion
Fully licensed producer in Alberta
Of the largest production facilities in
Canada
7.7M
Only
One

24. Aurora Sky Will Be the World’s Most Technologically Advanced And
Largest Capacity Cannabis Facility
• World leading design & supply partners
• First bays ready for planting
• Highest-yielding greenhouse per kWh of energy
consumed
• World’s first facility located at international
airport
• Estimated capital cost $120 million
• At full capacity, Aurora Sky is estimated to
produce over 100,000 kg per year
24
~800,000 square feet
100,000+ kg p.a.

25. Facility Features Aimed at Yield and Cost Optimization
• Forced air, over pressurized with tailored filters on inlet/outlet
• Sealed greenhouse enables energy conservation, minimizes
disease pressure
• Design supports unsurpassed light availability and penetration
• Best-in-class uniform climate control throughout grow zones
• Specialized irrigation system supports health, minimizes waste
• Focus on optimized yield, quality, flavor/aroma
• Fully integrated computer monitoring & control across entire
life cycle
• Mobile bench system and automated plant movement
• Integrated visual monitoring systems to identify pests, disease
and other problems
• Harvest to dry provides small-batch quality with mass scale
throughput
• Custom process-flow supports production under strict
GMP/GPP standards
Aurora Cannabis Inc. Management Presentation 25

26. Optimal Logistics at Edmonton International Airport (EIA)
Advantages
• Unparalleled access to transportation for
domestic and international distribution of
products servicing Aurora’s expanding
footprint
• Access to industrial infrastructure, power,
water and gas
• Federal security monitoring
• Co-location with bonded warehousing
and courier services
• Edmonton has the lowest corporate tax
rate in North America
• Property taxes at the Edmonton
International airport are approximately
half of those charged in Edmonton
Aurora Cannabis Inc. Management Presentation 26
AURORA SKY

27. Aurora Vie and Lachute Quebec facilities
• Acquired Peloton Pharmaceuticals for $7 million
• 40,000 square foot facility completed and first
planting commenced November 2017
• Completed build-out and received license in
November 2017, reflecting unparalleled execution
in sector
• Provides direct access to Quebec market
• Provides operations base to target, and shortens
supply lines to serve, Atlantic Provinces
• Delivers additional supply
• Certain technologies proposed for Aurora Sky to
be tested at Pointe-Claire facility
Aurora Cannabis Inc. Management Presentation 27
• H2 Biopharma acquired December 2017
• 48,000 sqft nearly completed facility
• 4,500 kg/yr capacity
• 46 acres expansion land under option to
acquire for $136,000

28. OUR PRODUCTS
28

29. Aurora Dried Flower Products Recognized for High Quality
WIDE RANGE OF HIGH-DEMAND PRODUCTS
• Highest CBD Strain in Canada
• Highest THC Strain in Canada
• Mid-range THC Strains
• Balanced THC/CBD Strains
The Aurora brand resonates with the Canadian Medical Cannabis Community and Adult Use Culture
24
10+
24
0
$9 per Gram; $6/gram compassionate pricing
Distinct Strains in Production ►
Dried Bud and Oils
Flagship Strains Differentiated by:
▪ THC%: < 1% – 32% (Highest reported in Canada)
▪ CBD%: < 0.5% – 20+% (Highest reported in Canada)
▪ Types: Indica, Sativa, Hybrid, Blend
Product Strains Launched to Date
Pesticides and Gamma-irradiation ►
Natural, Differentiated
Sundance
(Borealis Blend)
Ambition
(Blue Dream)
Sentinel
(Cannatonic)

30. Cannabis Oils – Sales & Continued Innovation
• Sales license received January 2017
• Sales of four product lines
commenced in April 2017
• Sales price - $95 per 30ml bottle
($65 compassionate pricing)
• Game-changing collaboration with Radient
• Proprietary technology with the potential for:
• Better Terpene preservation
• Significantly reduced extraction times (minutes vs
hours for current benchmark)
• Lower production costs
• Higher active ingredient purity
• Increased recovery of actives from scarce biomass
• Utilization of significantly less energy and material
inputs than current benchmark processes
• Collaboration grants exclusivity related to the
use of the technology in Canada
Aurora Cannabis Inc. Management Presentation 30

31. Product Differentiation – Enabling The Homegrow Market
Aurora Cannabis Inc. Management Presentation 31
Industry-leading grow boxes for the homegrow market
Urban cultivators for microgreens for both the residential
and commercial kitchen markets
Endorsed by celebrities and corporations

32. Hempco – New Products, New Markets, Low-Cost CBD Supply
Aurora Cannabis Inc. Management Presentation 32
One of the world’s largest industrial producers
of hemp products
• Primary product lines:
• Bulk and packaged food products (e.g. hemp protein
powder, hemp seeds or hearts, hemp oil
• Hemp fibre
• Nutraceuticals
• Animal feed supplement product line launched
• Hemp contains significant amounts of Omega
fatty acids with proven health benefits
• Hempco’s line of packaged foods are sold under
the brand “Planet Hemp” and are distributed
globally in seven countries
• Hemp is a potential source of CBD
Health Canada proposals would allow for whole-
plant utilization model, making hemp low-cost
source of CBD material

33. LEADERSHIP
33

34. Experienced Leadership Team
Aurora Cannabis Inc. Management Presentation 34
Terry Booth
CEO
CEO of 6 successful companies
25 years experience in highly
regulated industries
Cam Battley
Chief Corporate Officer
Deep experience in pharma and
cannabis sectors
Board member Cannabis
Canada
Steve Dobler
President
Successful entrepreneur, member of
many public companies’ board of
directors. Responsible for raising
substantial funds for Aurora
Glen Ibbott
CFO
Strong senior financial executive
with deep life sciences sector
experience
Neil Belot
Chief Global Business
Development Officer
Former executive director of
Cannabis Canada - Canada's trade
association for Licensed Producers
Allan Cleiren
COO
Experienced operational
executive with nearly three
decades leadership experience
at private and public companies
Darryl Vleeming
Chief Information Officer
over 20 years of experience in
Senior IT leadership, project
delivery, and IT strategic planning
at publicly traded international
corporations, with a specific
focus on driving business value.

35. Board of Directors
Aurora Cannabis Inc. Management Presentation 35
Steve Dobler
President, Aurora
Successful entrepreneur,
member of many public
companies’ board of
directors. Responsible for
raising substantial funds
for Aurora
Adam Szweras
Partner, Fogler, Rubinoff LLP
Experienced securities
lawyer. Founder of a US
developer of marijuana
and hemp oil, and edible
products.
Michael Singer
Chairman
CFO, Clementia
Pharmaceuticals
Former CFO, Bedrocan
Cannabis Corp.
Terry Booth
CEO, Aurora
CEO of 6 successful
companies
25 years experience
in highly regulated
industries
Dr. Jason Dyck
Professor, Department of
Pediatrics and Director of
Cardiovascular
Research Centre,
University of Alberta
Joseph del Moral
President, CanvasRx
Experienced executive in
regulated industries
Exited last company to Just
Energy (JE.TO)
Diane Jang
A business consultant,
specializing in strategic
planning for sustainable
success, growth and
profitability, with over 27
years of business
experience in the
Consumer Packaged
Goods industry

36. HIGHLIGHTS
36
Fastest patient sign up
rate in industry
Scale to service both
rapidly growing medical
market and seize
legalization opportunity
Extremely well capitalized
to pursue global
expansion opportunity
• Upon completion, five facilities
• ~ 200,000 kg per annum production capacity1
• Technologically most advanced facilities =>
ultra low cost of production
• Global reach
• Pedanios - Germany & EU
• Cann Group – Australia
• Aurora Nordic - Denmark
SCALE
• Disruptive extraction technology
• First mobile app for ordering medical cannabis
• Customer care: same day delivery in two
metropolitan areas
INNOVATION
• High quality products
• BC Northern Lights & Urban Cultivator: addressing home
grow and micro green markets
• Hempco Food & Fiber: new products, new health life-
style markets, low-cost source of CBD materia
• Namaste partnership delivering product differentiation
DIFFERENTIATION
1 prorated for 51% interest in Aurora Nordic and 17% interest in TGOD

37. 37
AGILITY INNOVATION EXECUTION EXPANSION
Talented, experienced management team driving the sector's
fastest growth in customers, revenues and shareholder value

38. Aurora Information
Established
2013
~500 Employees
7 Directors
Head Office
1500 -1199 West Hastings St.
Vancouver, BC V6E 3T5
TSX:
ACB
OTCQX:
ACBFF
Aurora Cannabis Inc. Management Presentation 38

39. Capital Summary
Market Cap - Basic
$6.5 Billion
Share Price -
January 8, 2018
$13.89
Aurora Cannabis Inc. Management Presentation 39
Strong balance sheet with pro-forma Cash and Marketable Securities Balance
> $700 million
January 8, 2018
TSX listed, ticker symbol ACB
Securities
Issued & Outstanding Shares 470,194,953
Options 21,580,724
Warrants 11,037,886
Restricted stock units 2,000,000
Convertible debentures shares
reserved for issuance
17,692,308
Fully Diluted 522,505,871

40. Contact Information
Cam Battley
Chief Corporate Officer
+1 (905) 878-5525
cam@auroramj.com
40
Marc Lakmaaker, Director IR &
Corporate Development
+1 (647) 269-5523
Marc.lakmaaker@auroramj.com